{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T03:00:12Z","timestamp":1768705212239,"version":"3.49.0"},"reference-count":46,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T00:00:00Z","timestamp":1620864000000},"content-version":"unspecified","delay-in-days":12,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011094","name":"Public Health Agency of Canada","doi-asserted-by":"publisher","award":["N\/A (PHAC does not provide grant numbers)"],"award-info":[{"award-number":["N\/A (PHAC does not provide grant numbers)"]}],"id":[{"id":"10.13039\/100011094","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2021,4,14]]},"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess the cost effectiveness of once weekly rifapentine and isoniazid for 12 weeks (3HP) to the current standard care for latent tuberculosis (TB) infection (LTBI) in Iqaluit, Nunavut.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>A cost-effectiveness analysis using a Markov model reflecting local practices for LTBI treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>A remote Canadian arctic community with a high incidence of TB.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Hypothetical patients with LTBI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions<\/jats:title>\n                    <jats:p>The cost effectiveness of 3HP was compared with the existing standard of care in the study region which consists of 9 months of twice weekly isoniazid (9H) given by directly observed therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcome measures<\/jats:title>\n                    <jats:p>Effectiveness was measured in quality-adjusted life years (QALYs) with model parameters were derived from historical programmatic data, a local implementation study of 3HP and published literature. Costs from the perspective of the Nunavut healthcare system were measured in 2019 US dollars and were obtained primarily from local, empirically collected data. Secondary health outcomes included estimated TB cases and TB deaths averted using 3HP versus 9H. One way and probabilistic sensitivity analyses were performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The 3HP regimen was dominant over 9H: costs were lower (US$628 vs US$924\/person) and health outcomes slightly improved (20.14 vs 20.13 QALYs\/person). In comparison to 9H, 3HP treatment resulted in fewer TB cases (27.89 vs 30.16\/1000 persons) and TB deaths (2.29 vs 2.48\/1000 persons). 3HP completion, initiation and risk of fatal adverse events were the primary drivers of cost effectiveness.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In a remote Canadian arctic setting, using 3HP instead of 9H for LTBI treatment may result in cost savings and similar or improved health outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2020-047514","type":"journal-article","created":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T13:21:20Z","timestamp":1620912080000},"page":"e047514","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":13,"title":["Cost-effectiveness analysis of 3 months of weekly rifapentine and isoniazid compared to isoniazid monotherapy in a Canadian arctic setting"],"prefix":"10.1136","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7244-7413","authenticated-orcid":false,"given":"Christopher","family":"Pease","sequence":"first","affiliation":[{"name":"Division of Respirology, Ottawa Hospital General Campus, Ottawa, Ontario, Canada"},{"name":"Ottawa Hospital Research Institute, Ottawa, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gonzalo","family":"Alvarez","sequence":"additional","affiliation":[{"name":"Division of Respirology, Ottawa Hospital General Campus, Ottawa, Ontario, Canada"},{"name":"Ottawa Hospital Research Institute, Ottawa, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ranjeeta","family":"Mallick","sequence":"additional","affiliation":[{"name":"Ottawa Hospital Research Institute, Ottawa, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mike","family":"Patterson","sequence":"additional","affiliation":[{"name":"Department of Health, Government of Nunavut, Iqaluit, Nunavut, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandy","family":"Finn","sequence":"additional","affiliation":[{"name":"Department of Health, Government of Nunavut, Iqaluit, Nunavut, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yahya","family":"Habis","sequence":"additional","affiliation":[{"name":"Deparment of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3354-1159","authenticated-orcid":false,"given":"Kevin","family":"Schwartzman","sequence":"additional","affiliation":[{"name":"Montreal Chest Institute, Montreal, Quebec, Canada"},{"name":"Department of Medicine, McGill University, Montreal, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elaine","family":"Kilabuk","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunita","family":"Mulpuru","sequence":"additional","affiliation":[{"name":"Division of Respirology, Ottawa Hospital General Campus, Ottawa, Ontario, Canada"},{"name":"Ottawa Hospital Research Institute, Ottawa, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Zwerling","sequence":"additional","affiliation":[{"name":"School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2021,5,13]]},"reference":[{"key":"2025121406560859000_11.5.e047514.1","doi-asserted-by":"crossref","first-page":"68","DOI":"10.14745\/ccdr.v45i23a04","article-title":"Tuberculosis in Canada: 2017","volume":"45","author":"LaFreniere","year":"2019","journal-title":"Can Commun Dis Rep"},{"key":"2025121406560859000_11.5.e047514.2","unstructured":"Canada IS, Canada IS . Eliminating Tuberculosis across Inuit Nunangat by 2030; at least a 50% reduction by 2025 [Internet]. gcnws, 2018. Available: https:\/\/www.canada.ca\/en\/indigenous-services-canada\/news\/2018\/03\/eliminating-tuberculosis-across-inuit-nunangat-by-2030-at-least-a-50-reduction-by-2025.html [Accessed 18 Jun 2018]."},{"key":"2025121406560859000_11.5.e047514.3","doi-asserted-by":"crossref","first-page":"82","DOI":"10.14745\/ccdr.v44i34a02","article-title":"Addressing tuberculosis among Inuit in Canada","volume":"44","author":"Patterson","year":"2018","journal-title":"Can Commun Dis Rep"},{"key":"2025121406560859000_11.5.e047514.4","unstructured":"Inuit Tuberculosis Elimination Framework [Internet]. Inuit Tapiriit Kanatami, 2018. Available: https:\/\/www.itk.ca\/wp-content\/uploads\/2018\/12\/FINAL-ElectronicEN-Inuit-TB-Elimination-Framework.pdf"},{"key":"2025121406560859000_11.5.e047514.5","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-publhealth-031912-114431"},{"key":"2025121406560859000_11.5.e047514.6","first-page":"555","article-title":"Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union against tuberculosis Committee on prophylaxis","volume":"60","year":"1982","journal-title":"Bull World Health Organ"},{"key":"2025121406560859000_11.5.e047514.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104875"},{"key":"2025121406560859000_11.5.e047514.8","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-017-2377-x"},{"key":"2025121406560859000_11.5.e047514.9","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1002\/pds.4423","article-title":"A systematic review of adverse events of rifapentine and isoniazid compared to other treatments for latent tuberculosis infection","volume":"27","author":"Pease","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2025121406560859000_11.5.e047514.10","unstructured":"List of Drugs for an Urgent Public Health Need [Internet] . Public health agency of Canada. Available: https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/access-drugs-exceptional-circumstances\/list-drugs-urgent-public-health-need.html [Accessed cited 2019 Nov 7]."},{"key":"2025121406560859000_11.5.e047514.11","doi-asserted-by":"crossref","DOI":"10.1080\/22423982.2020.1758501","article-title":"The implementation of rifapentine and isoniazid (3Hp) in two remote Arctic communities with a predominantly Inuit population, the Taima TB 3Hp study","volume":"79","author":"Alvarez","year":"2020","journal-title":"Int J Circumpolar Health"},{"key":"2025121406560859000_11.5.e047514.12","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.tmaid.2016.05.010","article-title":"Cost effectiveness of interferon-gamma release assay for tuberculosis screening using three months of rifapentine and isoniazid among long-term expatriates from low to high incidence countries","volume":"14","author":"Kowada","year":"2016","journal-title":"Travel Med Infect Dis"},{"key":"2025121406560859000_11.5.e047514.13","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.13.0423"},{"key":"2025121406560859000_11.5.e047514.14","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000004126","article-title":"Impacts of 12-dose regimen for latent tuberculosis infection: treatment completion rate and cost-effectiveness in Taiwan","volume":"95","author":"Huang","year":"2016","journal-title":"Medicine"},{"key":"2025121406560859000_11.5.e047514.15","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/cid\/ciy230","article-title":"Cost-Effectiveness of preventive therapy for tuberculosis with isoniazid and rifapentine versus isoniazid alone in high-burden settings","volume":"67","author":"Johnson","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2025121406560859000_11.5.e047514.16","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1093\/jac\/dky403","article-title":"Cost-effectiveness of 3\u2009months of weekly rifapentine and isoniazid compared with other standard treatment regimens for latent tuberculosis infection: a decision analysis study","volume":"74","author":"Doan","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2025121406560859000_11.5.e047514.17","unstructured":"Government of Canada SC . Census Profile, 2016 Census - Nunavut [Territory] and Iqaluit, City [Census subdivision], Nunavut [Internet], 2017. Available: http:\/\/www12.statcan.gc.ca\/census-recensement\/2016\/dp-pd\/prof\/details\/Page.cfm?Lang=E&Geo1=PR&Code1=62&Geo2=CSD&Code2=6204003&Data=Count&SearchText=Nunavut&SearchType=Begins&SearchPR=01&B1=All&GeoLevel=PR&GeoCode=62 [Accessed 18 Jun 2018]."},{"key":"2025121406560859000_11.5.e047514.18","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-019-4557-3","article-title":"The latent tuberculosis infection cascade of care in Iqaluit, Nunavut, 2012-2016","volume":"19","author":"Pease","year":"2019","journal-title":"BMC Infect Dis"},{"key":"2025121406560859000_11.5.e047514.19","unstructured":"Nunavut tuberculosis manual. government of Nunavut 2018."},{"key":"2025121406560859000_11.5.e047514.20","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.12195"},{"key":"2025121406560859000_11.5.e047514.21","unstructured":"Edejer T , Baltussen R , Adam T , et al . Who guide to cost-effectiveness analysis. World Health Organization, 2003."},{"key":"2025121406560859000_11.5.e047514.22","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1002\/pds.4423","article-title":"A systematic review of adverse events of rifapentine and isoniazid compared to other treatments for latent tuberculosis infection","volume":"27","author":"Pease","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2025121406560859000_11.5.e047514.23","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200901-0153OC"},{"key":"2025121406560859000_11.5.e047514.24","unstructured":"US Department of Health and Human Services . Common terminology criteria for adverse events (CTCAE), version 5. National Institutes of health National cancer Institute 2017."},{"key":"2025121406560859000_11.5.e047514.25","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.5588\/ijtld.14.0163","article-title":"Sputum induction for tuberculosis diagnosis in an Arctic setting: a cost comparison","volume":"18","author":"Sugarman","year":"2014","journal-title":"Int J Tuberc Lung Dis"},{"key":"2025121406560859000_11.5.e047514.26","unstructured":"Consumer Price Index . annual average, not seasonally adjusted [Internet]. Statistics Canada. Available: https:\/\/www150.statcan.gc.ca\/t1\/tbl1\/en\/tv.action?pid=1810000501"},{"key":"2025121406560859000_11.5.e047514.27","unstructured":"International Monetary Fund . IMF exchange rates database."},{"key":"2025121406560859000_11.5.e047514.28","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ766"},{"key":"2025121406560859000_11.5.e047514.29","unstructured":"Long R . Canada PHA of. Canadian tuberculosis standards 7th edition, 2014. Available: https:\/\/www.canada.ca\/en\/public-health\/services\/infectious-diseases\/canadian-tuberculosis-standards-7th-edition.html [Accessed 19 Nov 2017]."},{"key":"2025121406560859000_11.5.e047514.30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714283"},{"key":"2025121406560859000_11.5.e047514.31","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200510-1666ST"},{"key":"2025121406560859000_11.5.e047514.32","first-page":"28","article-title":"Controlled chemoprophylaxis trials in tuberculosis. A general review","volume":"26","author":"Ferebee","year":"1970","journal-title":"Bibl Tuberc"},{"key":"2025121406560859000_11.5.e047514.33","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm\/137.4.805"},{"key":"2025121406560859000_11.5.e047514.34","first-page":"847","article-title":"How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults?","volume":"3","author":"Comstock","year":"1999","journal-title":"Int J Tuberc Lung Dis"},{"key":"2025121406560859000_11.5.e047514.35","unstructured":"Public Health Agency of Canada . Tuberculosis in Canada 2008. Government of Canada, 2009."},{"key":"2025121406560859000_11.5.e047514.36","unstructured":"Public Health Agency of Canada . Tuberculosis in Canada 2009. Government of Canada, 2013."},{"key":"2025121406560859000_11.5.e047514.37","unstructured":"Public Health Agency of Canada . Tuberculosis in Canada 2010 \u2013 Pre-release. Government of Canada, 2012."},{"key":"2025121406560859000_11.5.e047514.38","unstructured":"Public Health Agency of Canada . Tuberculosis in Canada 2011 \u2013 Pre-Release. Government of Canada, 2012."},{"key":"2025121406560859000_11.5.e047514.39","unstructured":"Public Health Agency of Canada . Tuberculosis in Canada 2012. Government of Canada, 2014."},{"key":"2025121406560859000_11.5.e047514.40","unstructured":"Public Health Agency of Canada . Tuberculosis in Canada 2013 - Pre-release. Government of Canada, 2015."},{"key":"2025121406560859000_11.5.e047514.41","unstructured":"Public Health Agency of Canada . Tuberculosis in Canada 2014 \u2013 Pre-release. Government of Canada, 2016."},{"key":"2025121406560859000_11.5.e047514.42","doi-asserted-by":"crossref","first-page":"77","DOI":"10.14745\/ccdr.v43i34a04","article-title":"Tuberculosis in Canada - Summary 2015","volume":"43","author":"Gallant","year":"2017","journal-title":"Can Commun Dis Rep"},{"key":"2025121406560859000_11.5.e047514.43","doi-asserted-by":"crossref","first-page":"75","DOI":"10.14745\/ccdr.v44i34a01","article-title":"Tuberculosis in Canada, 2016","volume":"44","author":"Vachon","year":"2018","journal-title":"Can Commun Dis Rep"},{"key":"2025121406560859000_11.5.e047514.44","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-012-0329-x"},{"key":"2025121406560859000_11.5.e047514.45","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00159409"},{"key":"2025121406560859000_11.5.e047514.46","unstructured":"Canadian Institute for Health Information . Care in Canadian ICUs [Internet]. CIHI, 2016. Available: https:\/\/secure.cihi.ca\/free_products\/ICU_Report_EN.pdf"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2020-047514","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T14:56:16Z","timestamp":1765724176000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2020-047514"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":46,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,5,13]]},"published-print":{"date-parts":[[2021,5]]}},"alternative-id":["10.1136\/bmjopen-2020-047514"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2020-047514","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5]]}}}